我要投票 莎普爱思在滴眼液行业中的票数:381
· 外 推 电 报 ·
2025-07-01 14:12:21 星期二

【莎普爱思是哪个国家的品牌?】

莎普爱思是什么牌子?「莎普爱思」是 浙江莎普爱思药业股份有限公司 旗下著名品牌。该品牌发源于浙江,由创始人陈德康在2000-07-17期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力莎普爱思品牌出海!将品牌入驻外推网,定制莎普爱思品牌推广信息,可以显著提高莎普爱思产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

公司自1978年建厂以来,经历了从“国营浙江平湖制药厂”转制成“浙江平湖制药厂(股份合作)”到“浙江平湖莎普爱思制药有限公司”,再到“浙江莎普爱思制药有限公司”,最终于2008年12月15日更名为“浙江莎普爱思药业股份有限公司”,目前注册资金为4900万元人民币。

公司作为一家专业从事药品研发、生产、经营的综合性制药企业,先后被列为“国家高新技术企业”、“浙江省百家最具投资价值企业”、“浙江省千家成长之星企业”、“浙江省级企业技术中心”、“省级高新技术研究开发中心”、“浙江省标准创新型企业”、“嘉兴市重点企业技术创新团队”、“院士专家工作站”等多项荣誉称号。

目前公司拥有大容量注射剂(玻璃瓶、塑料瓶和多层共挤膜袋)、口服溶液剂、滴眼剂、片剂(含头孢菌素类)、硬胶囊剂(含头孢菌素类)、栓剂、颗粒剂(含头孢菌素类)、干混悬剂(含头孢菌素类)、冲洗剂共10个剂型,近百种规格的产品批准文号。抗白内障新药“莎普爱思”滴眼液和抗青光眼新药“达靓”滴眼液被列入“国家火炬计划项目”。“莎普爱思”滴眼液还荣获国家重点科技攻关项目、国家重点新产品、浙江省名牌产品等多个称号,是国内第一个国家二类眼科专科新药。

几十年来,公司凭着优质的产品,良好的信誉,在市场竞争日益激烈的情况下,赢得了市场,产品销往全国各地,取得了良好的经济效益。近年来公司的产品销量与销售额都呈现出逐年增涨的态势,是平湖市重点扶持的股改上市企业。

在竞争激烈的医药市场中,我公司始终坚持科技兴业、加强管理、保证质量,不断推出各种自主研发的新产品。公司秉承“科技创新、求是进取、优质高效、和谐健康”的企业精神,不断寻求创新与突破,逐步使公司成为现代化、高科技制药企业。

莎普爱思的未来将坚持以市场为导向,发展为主题,科技创新为核心。以保护和增进人民健康、提高人民福祉为目标。我们确信莎普爱思的无限“关爱”会遍及中国,走向世界。

英文翻译:Since its establishment in 1978, the company has gone through the transformation from "state-owned Zhejiang Pinghu pharmaceutical factory" to "Zhejiang Pinghu pharmaceutical factory (joint stock cooperation)" to "Zhejiang Pinghu sapais Pharmaceutical Co., Ltd." and then to "Zhejiang sapais Pharmaceutical Co., Ltd." and finally changed its name to "Zhejiang sapais pharmaceutical Co., Ltd." on December 15, 2008, with the current registered capital of 49 million yuan RMB. As a comprehensive pharmaceutical enterprise specializing in drug R & D, production and operation, the company has been listed as "national high-tech enterprise", "one hundred enterprises with the most investment value in Zhejiang Province", "one thousand growth star enterprises in Zhejiang Province", "Zhejiang provincial enterprise technology center", "provincial high-tech research and development center", "Zhejiang standard innovation enterprise" "Jiaxing key enterprise technology innovation team", "academician expert workstation" and other honorary titles. At present, the company has 10 dosage forms of large capacity injection (glass bottles, plastic bottles and multi-layer coextrusion film bags), oral solution, eye drops, tablets (including cephalosporins), hard capsules (including cephalosporins), suppositories, granules (including cephalosporins), dry suspension (including cephalosporins), washing agents, and approval numbers of nearly 100 specifications of products. The new anti cataract drug "sapais" eye drops and the new anti glaucoma drug "Daliang" eye drops are listed in the "National Torch Program project". "Saps eye drops" also won the titles of national key scientific and technological research projects, national key new products, Zhejiang famous brand products, etc., and is the first national class II ophthalmic specialty new drug in China. In the past few decades, with its high quality products and good reputation, the company has won the market and sold its products to all parts of the country under the increasingly fierce market competition, and achieved good economic benefits. In recent years, the sales volume and sales volume of the company have been increasing year by year. It is a listed company supported by Pinghu City. In the highly competitive pharmaceutical market, our company always adheres to the development of science and technology, strengthening management, ensuring quality, and constantly launches various new products independently researched and developed. The company adheres to the enterprise spirit of "scientific and technological innovation, truth-seeking and enterprising, high-quality and efficient, harmonious and healthy", constantly seeks innovation and breakthrough, and gradually makes the company become a modern, high-tech pharmaceutical enterprise. In the future, SAPS will adhere to the market-oriented, development oriented theme and technological innovation as the core. With the goal of protecting and promoting people's health and improving people's well-being. We are sure that the infinite "love" of sapeus will spread all over China and go to the world.

本文链接: https://www.waitui.com/brand/a5a71ec58.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

生成超1000万份志愿报告,夸克实现国内最大规模深度研究应用

7月1日,阿里巴巴AI旗舰应用夸克已累计为考生和家长生成超1000万份专业级志愿报告。这些报告由今年推出的“志愿报告”Agent生成,采用了具备“任务规划—执行—检查—反思”能力的深度研究技术。业内认为,这一成果已成为国内最大规模的深度研究技术应用。“志愿报告”是今年夸克针对志愿填报推出的核心功能,也是国内唯一可以生成完整志愿报告的Agent。

13分钟前

阿维塔:6月交付10153台,同比增长117%

36氪获悉,据阿维塔官微,阿维塔6月销量10153辆,同比增长117%,连续四月销量破万。

13分钟前

深圳华强成立电子公司,含数字技术服务业务

36氪获悉,爱企查App显示,近日,深圳聚华芯电子有限公司成立,法定代表人为陈俊彬,注册资本200万元人民币,经营范围包括电子产品销售、数字技术服务、电子元器件批发、电子元器件零售、电工仪器仪表销售、智能仪器仪表销售、数字视频监控系统销售等。股权穿透图显示,该公司由深圳华强实业股份有限公司旗下深圳华强实业股份有限公司全资持股。

13分钟前

军工板块探底回升,长城军工再度涨停

36氪获悉,截至发稿,军工板块探底回升,长城军工再度涨停,走出10天8板,中船应急、利君股份、四创电子、际华集团等多股封板,中科海讯涨超10%。

13分钟前

央行征信中心:7月1日起全面执行征信服务新收费标准

36氪获悉,据中国人民银行征信中心消息,根据《国家发展改革委关于进一步降低征信服务收费标准的通知》(发展价格〔2025〕668号),中国人民银行征信中心自2025年7月1日起全面执行征信服务新收费标准。个人柜台查询自身信用报告,每年前2次免费,自第3次起的收费标准为每次5元。个人通过互联网查询自身信用报告免费。

13分钟前

本页详细列出关于莎普爱思的品牌信息,含品牌所属公司介绍,莎普爱思所处行业的品牌地位及优势。
咨询